{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10060","date":"2024-07-23T16:00:00.000Z","role":"Approver"},{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10060","date":"2024-09-26T15:27:01.798Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"evidence":[{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:de247657-2a36-4759-8053-29613ea6fdd9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:de247657-2a36-4759-8053-29613ea6fdd9","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:d05de6ec-f712-4e74-a381-29b0d4f80f58","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1677C>A (p.Tyr559Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA248377"}},{"id":"cggv:9380e7d5-c28b-4b13-b41e-96199d21d288","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1883A>G (p.Asp628Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312151"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Tonus dis-regulation, enlarged cerebrospinal fluid space, probable brain atrophy, history of infantile spasms, tonic seizures, PEG-tube feeding, severe constipation, abnormal EEG","phenotypes":["obo:HP_0001252","obo:HP_0001263","obo:HP_0001344","obo:HP_0000486","obo:HP_0002540"],"sex":"Male","variant":[{"id":"cggv:c328047f-7801-4db7-a803-cd8884f0b372_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9380e7d5-c28b-4b13-b41e-96199d21d288"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26299366","type":"dc:BibliographicResource","dc:abstract":"Using whole-exome sequencing, we have identified in ten families 14 individuals with microcephaly, developmental delay, intellectual disability, hypotonia, spasticity, seizures, sensorineural hearing loss, cortical visual impairment, and rare autosomal-recessive predicted pathogenic variants in spermatogenesis-associated protein 5 (SPATA5). SPATA5 encodes a ubiquitously expressed member of the ATPase associated with diverse activities (AAA) protein family and is involved in mitochondrial morphogenesis during early spermatogenesis. It might also play a role in post-translational modification during cell differentiation in neuronal development. Mutations in SPATA5 might affect brain development and function, resulting in microcephaly, developmental delay, and intellectual disability.","dc:creator":"Tanaka AJ","dc:date":"2015","dc:title":"Mutations in SPATA5 Are Associated with Microcephaly, Intellectual Disability, Seizures, and Hearing Loss."}},{"id":"cggv:be492d5a-fb06-4703-8547-c4cf47c1f22c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d05de6ec-f712-4e74-a381-29b0d4f80f58"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Individual 12"},{"id":"cggv:c328047f-7801-4db7-a803-cd8884f0b372","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:c328047f-7801-4db7-a803-cd8884f0b372_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:be492d5a-fb06-4703-8547-c4cf47c1f22c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:be492d5a-fb06-4703-8547-c4cf47c1f22c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ab9e645a-38ef-4665-842d-c0d6cc67a42a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ab9e645a-38ef-4665-842d-c0d6cc67a42a","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:845b2f65-6413-42f0-86f1-6b44dac33502","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.251G>A (p.Arg84Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312165"}},{"id":"cggv:25468902-0c74-4cab-b196-95aa1cbdbc04","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.2362_2371del (p.Ile788SerfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312157"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"peripheral hypotonia, cannot sit, possibly dismyelination, infantile spams starting at 3 month, epilepsy until 1 years and currently more, EEG abnormality(multi-focal spike), FTT, G-tube","phenotypes":["obo:HP_0008504","obo:HP_0000486","obo:HP_0002540","obo:HP_0001344","obo:HP_0008936","obo:HP_0011451","obo:HP_0001257","obo:HP_0001263","obo:HP_0012448"],"sex":"Female","variant":[{"id":"cggv:e56b87d1-bb96-4f2c-a212-f6140d84bc2b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:845b2f65-6413-42f0-86f1-6b44dac33502"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:97a9da28-44f8-4abd-a723-a4980c9b58b4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:25468902-0c74-4cab-b196-95aa1cbdbc04"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 3"},{"id":"cggv:97a9da28-44f8-4abd-a723-a4980c9b58b4","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:97a9da28-44f8-4abd-a723-a4980c9b58b4_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:e56b87d1-bb96-4f2c-a212-f6140d84bc2b","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e56b87d1-bb96-4f2c-a212-f6140d84bc2b_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7e46080d-055f-4fe6-aa8b-9ef36f45746b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7e46080d-055f-4fe6-aa8b-9ef36f45746b","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"cggv:845b2f65-6413-42f0-86f1-6b44dac33502"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"truncal hypotonia, peripheral spascity, myopia, astigmatism, visual disinterest, FTT","phenotypes":["obo:HP_0001263","obo:HP_0001252","obo:HP_0002353","obo:HP_0008504","obo:HP_0001250","obo:HP_0011451"],"sex":"Female","variant":{"id":"cggv:91c46380-d5af-400d-8694-b4e708785482_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:845b2f65-6413-42f0-86f1-6b44dac33502"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},"rdfs:label":"Individual 14"},{"id":"cggv:91c46380-d5af-400d-8694-b4e708785482","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:91c46380-d5af-400d-8694-b4e708785482_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:aed83f2e-ca15-4092-a682-fd013c625054_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:aed83f2e-ca15-4092-a682-fd013c625054","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:8e67610c-92a8-4210-9715-7db256988155","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.2384C>G (p.Pro795Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358230595"}},{"id":"cggv:9319b5a3-b2e9-4eb6-ade4-1fc23cb7f46f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.700C>T (p.Gln234Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358101855"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Microcephaly, Developmental delay,  cannot sit unsupported, absent speech, myoclonic, Spasticity, dystonia, axial hypotonia, peripheral hypertonic, hyperreflexia, Visual impairment, SNHL, Bilateral hip dislocation, dysplasia , severe gastro-oesophageal reflux and dysmotility, puree feeding, abnormal EEG, Marked cerebral atrophy, global leukodystrophy with relative preservation of the grey matter and of basal ganglia","sex":"Female","variant":[{"id":"cggv:ca443c18-d3d0-4e15-adb3-5ebd02221a91_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8e67610c-92a8-4210-9715-7db256988155"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29343804","type":"dc:BibliographicResource","dc:abstract":"Variants in the SPATA5 gene were recently described in a cohort of patients with global developmental delay, sensorineural hearing loss, seizures, cortical visual impairment and microcephaly. SPATA5 protein localizes predominantly in the mitochondria and is proposed to be involved in mitochondrial function and brain developmental processes. However no functional studies have been performed. This study describes five patients with psychomotor developmental delay, microcephaly, epilepsy and hearing impairment, who were thought clinically to have a mitochondrial disease with subsequent whole-exome sequencing analysis detecting compound heterozygous variants in the SPATA5 gene. A summary of clinical data of all the SPATA5 patients reported in the literature confirms the characteristic phenotype. To assess SPATA5's role in mitochondrial dynamics, functional studies were performed on rat cortical neurons. SPATA5-deficient neurons had a significant imbalance in the mitochondrial fusion-fission rate, impaired energy production and short axons. In conclusion, SPATA5 protein has an important role in mitochondrial dynamics and axonal growth. Biallelic variants in the SPATA5 gene can affect mitochondria in cortical neurons and should be considered in patients with a neurodegenerative disorder and/or with clinical presentation resembling a mitochondrial disorder.","dc:creator":"Puusepp S","dc:date":"2018","dc:title":"Compound heterozygous SPATA5 variants in four families and functional studies of SPATA5 deficiency."}},{"id":"cggv:b08f3a36-3ec0-4448-bc61-700691bd93df_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9319b5a3-b2e9-4eb6-ade4-1fc23cb7f46f"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"}],"rdfs:label":"Puusepp _ Patient 5"},{"id":"cggv:ca443c18-d3d0-4e15-adb3-5ebd02221a91","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ca443c18-d3d0-4e15-adb3-5ebd02221a91_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:b08f3a36-3ec0-4448-bc61-700691bd93df","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b08f3a36-3ec0-4448-bc61-700691bd93df_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:f94a890c-e115-4747-a1fe-07ea7f3eb625_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:f94a890c-e115-4747-a1fe-07ea7f3eb625","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":[{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.989_991del (p.Thr330del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA248379"}},{"id":"cggv:9c225f32-c22a-46d8-b2d0-5fee3419d691","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.394C>T (p.Gln132Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358100087"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"microcephaly, developmental delay, no speech, Tonic myoclonic, spasticity, dystonia, axial hypotonia, orofacial dyskinesia, Hyperreflexia, SNHL, cortical visual impairment, pendel nystagmus, abnormal EEG, development of hypoplasia of corpus callosum, delayed myelination appeared at 14 m, progressive white matter atrophy, ","sex":"Male","variant":[{"id":"cggv:e9248aec-a960-45f1-9d75-3e4d9ff5efb4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"},{"id":"cggv:1bb0c65a-602f-4247-b3a3-79d9d73ed69c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9c225f32-c22a-46d8-b2d0-5fee3419d691"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"}],"rdfs:label":"Puusepp _ Patient 4"},{"id":"cggv:1bb0c65a-602f-4247-b3a3-79d9d73ed69c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:1bb0c65a-602f-4247-b3a3-79d9d73ed69c_variant_evidence_item"}],"strengthScore":1,"dc:description":"This score is adjusted to reduce the proband score from 3.5 to 3.0 total points. Otherwise, the default score of 1.5 points is correct."},{"id":"cggv:e9248aec-a960-45f1-9d75-3e4d9ff5efb4","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e9248aec-a960-45f1-9d75-3e4d9ff5efb4_variant_evidence_item"},{"id":"cggv:e9248aec-a960-45f1-9d75-3e4d9ff5efb4_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"T330del mutant remarkably reduced SPATA5 melting temperature and slightly decreased association with SPATA5L1 and CINP (PMID: 38554706)"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:cef17223-fa39-4397-bf71-68e75e8bded5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:cef17223-fa39-4397-bf71-68e75e8bded5","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:2c2add56-7cf7-46be-b2b3-70850312ce8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1343C>T (p.Ser448Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA206522"}},{"id":"cggv:1e513fde-5654-478c-ab4f-88692a99ad7e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.556C>T (p.Arg186Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA208284"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"discoordinated eye movement, exotropia , possible refractive , amblyopia , small optic  disc, FTT, GERD, constipation , vomiting","phenotypes":["obo:HP_0002353","obo:HP_0011451","obo:HP_0001250","obo:HP_0002540","obo:HP_0001344","obo:HP_0001252","obo:HP_0001263"],"sex":"Female","variant":[{"id":"cggv:1ee91066-f0aa-4078-8a04-fe7296c9920b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1e513fde-5654-478c-ab4f-88692a99ad7e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:1bef93e9-b4ef-42fe-a263-2370bc170255_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2c2add56-7cf7-46be-b2b3-70850312ce8e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 4"},{"id":"cggv:1ee91066-f0aa-4078-8a04-fe7296c9920b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:1ee91066-f0aa-4078-8a04-fe7296c9920b_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:1bef93e9-b4ef-42fe-a263-2370bc170255","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:1bef93e9-b4ef-42fe-a263-2370bc170255_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:14b2a69b-e099-444f-9fae-5b4362ee9351_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:14b2a69b-e099-444f-9fae-5b4362ee9351","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},{"id":"cggv:2002484a-3a32-4479-a4b6-d5a1dbc0d60e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.250C>T (p.Arg84Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3070167"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"2y3m puree feeding, Progressive brain atrophy and atrophic caudate nucleus. Slightly elevated signal intensity on T2-weighted images in white matter, Relatively big ears, up-slanted palpebral fissures, high narrow palate, rethrognathia","phenotypes":["obo:HP_0002421","obo:HP_0002179","obo:HP_0000407","obo:HP_0002353","obo:HP_0001263","obo:HP_0001257","obo:HP_0011451","obo:HP_0001332","obo:HP_0001344"],"sex":"Female","variant":[{"id":"cggv:8fbd8c46-02c9-440c-be8d-d0eaa8e9bcf6_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2002484a-3a32-4479-a4b6-d5a1dbc0d60e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"},{"id":"cggv:2a82718f-654e-4afd-b68b-1d05d3066d6a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"}],"rdfs:label":"Puusepp _ Patient 1"},{"id":"cggv:8fbd8c46-02c9-440c-be8d-d0eaa8e9bcf6","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:8fbd8c46-02c9-440c-be8d-d0eaa8e9bcf6_variant_evidence_item"}],"strengthScore":1,"dc:description":"This score is adjusted to reduce the proband score from 3.5 to 3.0 total points. Otherwise, the default score of 1.5 points is correct. "},{"id":"cggv:2a82718f-654e-4afd-b68b-1d05d3066d6a","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2a82718f-654e-4afd-b68b-1d05d3066d6a_variant_evidence_item"},{"id":"cggv:2a82718f-654e-4afd-b68b-1d05d3066d6a_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"T330del mutant remarkably reduced SPATA5 melting temperature and slightly decreased association with SPATA5L1 and CINP (PMID: 38554706)"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:a3aadcb6-a2bd-49fb-a54d-936e6b037f96_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:a3aadcb6-a2bd-49fb-a54d-936e6b037f96","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":19,"allele":[{"id":"cggv:d6e77041-ec85-49a8-b4a6-054cd812cfb6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1586G>A (p.Arg529Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312149"}},{"id":"cggv:9380e7d5-c28b-4b13-b41e-96199d21d288"}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"peripheral hypotonia, spastic quadriplegia, retrocollis, nystigmus, cortical atrophy, immature myelationtion in occipital and frontal regions, possible coronal suture, epileptic encephalopathy, G-Tube","phenotypes":["obo:HP_0100704","obo:HP_0001344","obo:HP_0008504","obo:HP_0001263","obo:HP_0002721","obo:HP_0002353","obo:HP_0001873","obo:HP_0001250","obo:HP_0002540"],"sex":"Male","variant":[{"id":"cggv:454f244e-bdb2-4bd2-8cc4-435abe0f11d4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:d6e77041-ec85-49a8-b4a6-054cd812cfb6"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:249a8745-f48b-4ceb-a7fa-13065c6bb738_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9380e7d5-c28b-4b13-b41e-96199d21d288"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 8"},{"id":"cggv:454f244e-bdb2-4bd2-8cc4-435abe0f11d4","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:454f244e-bdb2-4bd2-8cc4-435abe0f11d4_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:249a8745-f48b-4ceb-a7fa-13065c6bb738","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:249a8745-f48b-4ceb-a7fa-13065c6bb738_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:ec896e92-1cdb-436b-8a3d-bc74d9bdb8ff_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ec896e92-1cdb-436b-8a3d-bc74d9bdb8ff","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":[{"id":"cggv:95158159-7c33-493a-b170-5b1d1b55f156","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1714+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA319623"}},{"id":"cggv:5bac7a04-1a0d-44ca-8e26-6581060af77b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1878G>C (p.Trp626Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA319621"}}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"infantile spasms, tonic seizures started at 7 months, GERD, G-tube ","phenotypes":["obo:HP_0011451","obo:HP_0001252","obo:HP_0001257","obo:HP_0001344","obo:HP_0002540","obo:HP_0001263","obo:HP_0002353","obo:HP_0100704","obo:HP_0008504"],"sex":"Male","variant":[{"id":"cggv:ac273f49-ff1a-431b-9377-fd68c71b4c88_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5bac7a04-1a0d-44ca-8e26-6581060af77b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:45108626-f43e-4538-a79e-502783a57797_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:95158159-7c33-493a-b170-5b1d1b55f156"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Individual 10"},{"id":"cggv:45108626-f43e-4538-a79e-502783a57797","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:45108626-f43e-4538-a79e-502783a57797_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:ac273f49-ff1a-431b-9377-fd68c71b4c88","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:ac273f49-ff1a-431b-9377-fd68c71b4c88_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:3b70c73b-3813-4d37-a34c-491779649ed9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:3b70c73b-3813-4d37-a34c-491779649ed9","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},"phenotypeFreeText":"hypertonia in the extremities, exotopia, mildly specked aspect of the retina, history of infantile spasms starting at 5 months, tonic seizures, trouble eating solid food ","phenotypes":["obo:HP_0011451","obo:HP_0100704","obo:HP_0002353","obo:HP_0008504","obo:HP_0008936","obo:HP_0002540"],"sex":"Female","variant":{"id":"cggv:5c80d643-bbb8-4077-8241-37d18cef1d81_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},"rdfs:label":"Patient 13"},{"id":"cggv:5c80d643-bbb8-4077-8241-37d18cef1d81","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:5c80d643-bbb8-4077-8241-37d18cef1d81_variant_evidence_item"},{"id":"cggv:5c80d643-bbb8-4077-8241-37d18cef1d81_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"T330del mutant remarkably reduced SPATA5 melting temperature and slightly\ndecreased association with SPATA5L1 and CINP (PMID: 38554706)\n"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:bc9a0fc0-dc19-4f63-83fb-4fb29e6563a2_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:bc9a0fc0-dc19-4f63-83fb-4fb29e6563a2","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":[{"id":"cggv:fca05e76-d9b7-44e4-bc68-e18fb0c5f74d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.1574_1578del (p.Asn525ThrfsTer20)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312158"}},{"id":"cggv:c1b96e94-192c-4b47-b257-39110e221221","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.2531C>T (p.Ala844Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA207576"}}],"detectionMethod":"WES","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"hypotonia in early infancy, spastic quadriplegia, cannot sit, progressive atrophy and hypoplasia of the corpus callosum","phenotypes":["obo:HP_0002353","obo:HP_0001257","obo:HP_0001263","obo:HP_0001344","obo:HP_0002179","obo:HP_0002721","obo:HP_0100704","obo:HP_0011451","obo:HP_0002019","obo:HP_0002540","obo:HP_0008504"],"sex":"Female","variant":[{"id":"cggv:6c48a45a-4ec6-4e86-8cc9-adf1947756a2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c1b96e94-192c-4b47-b257-39110e221221"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:b92993ca-962a-4b94-a63d-1f08b7e8bd9b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:fca05e76-d9b7-44e4-bc68-e18fb0c5f74d"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 1"},{"id":"cggv:b92993ca-962a-4b94-a63d-1f08b7e8bd9b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b92993ca-962a-4b94-a63d-1f08b7e8bd9b_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:6c48a45a-4ec6-4e86-8cc9-adf1947756a2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:6c48a45a-4ec6-4e86-8cc9-adf1947756a2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:131db898-9aa6-4553-8072-26714f7c3354_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:131db898-9aa6-4553-8072-26714f7c3354","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":9,"allele":[{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},{"id":"cggv:b919f460-7fa7-4b0e-8f07-7fdf7cd45672","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.554G>A (p.Gly185Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA3070271"}}],"phenotypeFreeText":"Microcephaly, absent speech, Clonic, tonic–clonic seizures, Spasticity, dystonia, SNHL, Hyperreflexia, Visual impairment, Strabismus, Hip dysplasia, Recurrent gastroenteritis, Mild rethrognathia","sex":"Female","variant":[{"id":"cggv:614168eb-5e65-4683-9e4d-e26fced33dca_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b919f460-7fa7-4b0e-8f07-7fdf7cd45672"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"},{"id":"cggv:c5eb1065-ba30-4968-ab11-b88674cc9a27_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b7c282f3-f02d-4803-88e4-f9c39e000418"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804"}],"rdfs:label":"Puusepp _ Patient 3"},{"id":"cggv:614168eb-5e65-4683-9e4d-e26fced33dca","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:614168eb-5e65-4683-9e4d-e26fced33dca_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:c5eb1065-ba30-4968-ab11-b88674cc9a27","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:c5eb1065-ba30-4968-ab11-b88674cc9a27_variant_evidence_item"},{"id":"cggv:c5eb1065-ba30-4968-ab11-b88674cc9a27_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"T330del mutant remarkably reduced SPATA5 melting temperature and slightly decreased association with SPATA5L1 and CINP (PMID: 38554706)\n"}],"strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:7feeea3d-14d2-41c5-bdf6-4fa32c9dcbf5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:7feeea3d-14d2-41c5-bdf6-4fa32c9dcbf5","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":[{"id":"cggv:15c9e63a-96ca-48df-9d8c-cab9ebfac70b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.298G>A (p.Ala100Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA205606"}},{"id":"cggv:1e513fde-5654-478c-ab4f-88692a99ad7e"}],"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Dystonic spasms, hypomyelination, epileptic spams (10-12 per day starting at 3 months), FTT, G-tube, GERD","phenotypes":["obo:HP_0002179","obo:HP_0001263","obo:HP_0002353","obo:HP_0011451","obo:HP_0001332","obo:HP_0008504","obo:HP_0001344","obo:HP_0001252","obo:HP_0100704","obo:HP_0002540"],"sex":"Female","variant":[{"id":"cggv:cd449100-2916-419c-bda4-11ab46a1fcbb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:15c9e63a-96ca-48df-9d8c-cab9ebfac70b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:f5f5d5b9-a4ab-4e8b-8441-ea68bd962e8b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1e513fde-5654-478c-ab4f-88692a99ad7e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 5"},{"id":"cggv:f5f5d5b9-a4ab-4e8b-8441-ea68bd962e8b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:f5f5d5b9-a4ab-4e8b-8441-ea68bd962e8b_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:cd449100-2916-419c-bda4-11ab46a1fcbb","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:cd449100-2916-419c-bda4-11ab46a1fcbb_variant_evidence_item"},{"id":"cggv:cd449100-2916-419c-bda4-11ab46a1fcbb_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"A100T remarkably reduced SPATA5 melting temperature, indicating that this mutation dramatically affect SPATA5 stability (PMID: 38554706)\n"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:25198c10-39f0-4363-8d2d-c122263839b8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:25198c10-39f0-4363-8d2d-c122263839b8","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":[{"id":"cggv:51790fb3-4227-415e-ac96-28933a172899","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.2351G>A (p.Arg784Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312161"}},{"id":"cggv:21ad5caf-487d-487a-a704-3c0619f2aee3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_145207.3(AFG2A):c.269G>T (p.Ser90Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA312159"}}],"phenotypeFreeText":"spastic quadriplegia, cannot sit, progressive diffuse atrophy, extra-axial arachnoid collections, intractable seizures  starting at 9 months, does not eat solid food, severe chronic autoimmune thrombocytopenia noted at birth","phenotypes":["obo:HP_0001344","obo:HP_0011451","obo:HP_0002353","obo:HP_0002540","obo:HP_0008504","obo:HP_0100704","obo:HP_0001263","obo:HP_0001252"],"sex":"Male","variant":[{"id":"cggv:69f7c1c9-581d-4c44-a432-2c06a2f28720_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:51790fb3-4227-415e-ac96-28933a172899"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"},{"id":"cggv:6a3ea951-4592-46c6-8db6-99b5cb5fdde9_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:21ad5caf-487d-487a-a704-3c0619f2aee3"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26299366"}],"rdfs:label":"Patient 6"},{"id":"cggv:69f7c1c9-581d-4c44-a432-2c06a2f28720","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:69f7c1c9-581d-4c44-a432-2c06a2f28720_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:6a3ea951-4592-46c6-8db6-99b5cb5fdde9","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:6a3ea951-4592-46c6-8db6-99b5cb5fdde9_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:90922927-aec5-4a83-8874-8a37292d7c67","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:83242e83-c863-4947-a31e-cb5b9322b6c6","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"Alterations in 55LCC-dependent replisome processing and the resultant genome instability may contribute to a subset of phenotypes in the microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/38554706","type":"dc:BibliographicResource","dc:abstract":"Ubiquitin-dependent unfolding of the CMG helicase by VCP/p97 is required to terminate DNA replication. Other replisome components are not processed in the same fashion, suggesting that additional mechanisms underlie replication protein turnover. Here, we identify replisome factor interactions with a protein complex composed of AAA+ ATPases SPATA5-SPATA5L1 together with heterodimeric partners C1orf109-CINP (55LCC). An integrative structural biology approach revealed a molecular architecture of SPATA5-SPATA5L1 N-terminal domains interacting with C1orf109-CINP to form a funnel-like structure above a cylindrically shaped ATPase motor. Deficiency in the 55LCC complex elicited ubiquitin-independent proteotoxicity, replication stress, and severe chromosome instability. 55LCC showed ATPase activity that was specifically enhanced by replication fork DNA and was coupled to cysteine protease-dependent cleavage of replisome substrates in response to replication fork damage. These findings define 55LCC-mediated proteostasis as critical for replication fork progression and genome stability and provide a rationale for pathogenic variants seen in associated human neurodevelopmental disorders.","dc:creator":"Krishnamoorthy V","dc:date":"2024","dc:title":"The SPATA5-SPATA5L1 ATPase complex directs replisome proteostasis to ensure genome integrity."},"rdfs:label":"Electrophoretic mobility shift assays and Western blot"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:3bf771e6-9991-4e3f-843f-6bf93e984202","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:3693a8f8-c801-46d6-8095-507cf2f2d3f8","type":"FunctionalAlteration","dc:description":"SPATA5-deficiency leads to impaired axogenesis in vitro, in primary cortical neurons. \nOverexpression of human shRNA-insensitive SPATA5 restored the axonal growth in the SPATA5 shRNA-treated group.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804","rdfs:label":"SPATA5-deficiency impairs neuronal growth  "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"cggv:f7a95952-8558-44e7-a2b7-a25d49de6325","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:f6836d1d-c7a8-43a8-ba2a-e6db5fc0ba68","type":"FunctionalAlteration","dc:description":"SPATA5-deficient neurons had a significant imbalance in the mitochondrial fusion-fission rate and impaired energy production. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29343804","rdfs:label":"SPATA5 shRNA-treated neurons "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Definitive","sequence":9047,"specifiedBy":"GeneValidityCriteria10","strengthScore":13.5,"subject":{"id":"cggv:1d594d87-b90b-4cef-9840-237cf65f2101","type":"GeneValidityProposition","disease":"obo:MONDO_0800439","gene":"hgnc:18119","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"The *AFG2A* gene is located on chromosome 4 at 4q28.1 and encodes a member of the ATPase associated with diverse activities (AAA) protein family. *AFG2A* was first reported in connection with autosomal recessive syndromic complex neurodevelopmental disorder in 2015 (Tanaka et al., 2015 PMID: 26299366). Affected individuals are characterized by microcephaly, global developmental delay, intellectual disability, abnormal muscle tone, and sensorineural hearing impairment. Additional variable manifestations include epilepsy, cortical visual impairment, gastrointestinal disturbances, growth restriction, scoliosis, as well as immunodeficiency and thrombocytopenia. Brain imaging may show cerebral atrophy, thin corpus callosum, and hypomyelination. \n\nTwenty variants (11 missense, 5 nonsense, 2 frameshift, 1 canonical splice site, 1 deletion) reported in 18 probands across 2 publications are included in this curation (PMIDs: 29343804, 26299366). The mechanism of disease is reported to be loss-of-function. The maximum points for genetic evidence (12pts) was reached, however, additional cases are available in the literature (PMIDs: 34949788, 27246907). This gene-disease relationship is also supported by experimental evidence including functional alteration in non-patient cells and biochemical function (PMIDs: 29343804, 38554706). \n\nIn summary, there is definitive evidence supporting the relationship between *AFG2A* and autosomal recessive syndromic complex neurodevelopmental disorder.  This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date July 23rd, 2024 (SOP Version 10).","dc:isVersionOf":{"id":"cggv:c3ae4261-8438-496b-8295-a9fdb5785436"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}